NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
March 29, 2005 • Volume 2 / Number 13 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Monoclonal Antibody Therapy for Treatment-Resistant
Blood Cancers

Name of the Trial
Phase I Study of Siplizumab (MEDI-507) in Patients with CD2-Positive Lymphoproliferative Disorders (NCI-04-C-0031). See the protocol summary at

Principal Investigator
Dr. John Edward Janik, NCI's CCR

Why Is This Trial Important?
Lymphoproliferative disorders, such as leukemias and lymphomas, are diseases in which cells of the lymphatic system (lymphocytes) grow excessively. These cancers can be especially hard to treat effectively if they arise from a malfunction in one type of lymphocyte called a T cell.

Siplizumab is a monoclonal antibody that binds to a protein called CD2, which is found abundantly on certain types of lymphocytes including T cells and Natural Killer (NK) cells. Initially developed to treat psoriasis, siplizumab has been shown in clinical studies to trigger T-cell death. This phase I dose-escalation study is investigating safety and tolerability, and will determine the maximum dose of siplizumab that can be given to patients with CD2-positive lymphoproliferative disease.

Dr. John Edward Janik"Preclinical studies of siplizumab at NCI produced very promising results, with a short course of treatment yielding a 50 percent cure rate in mice with T-cell non-Hodgkin's lymphoma," said Dr. Janik. "Longer courses of treatment led to the treated mice living out their natural life spans.

"Early results from this trial have produced promising responses in some patients, and we hope to follow this research with additional studies combining siplizumab and chemotherapy," Dr. Janik added.

Who Can Join This Trial?
Researchers seek to enroll up to 24 additional patients aged 18 or older with CD2-positive lymphomas or leukemias that have been unresponsive to previous treatment. See the full list of eligibility criteria at

Where Is This Trial Taking Place?
This trial is being conducted at the NIH Clinical Center in Bethesda, Md.

Contact Information
For more information, call the NCI Clinical Studies Support Center (CSSC) at 1-888-NCI-1937. The call is toll free and completely confidential.

An archive of "Featured Clinical Trial" columns is available at